Well Endocrinology · Hinsdale, IL
What Your Doctor Never Told You About Perimenopause
The hormonal shifts that begin years before your last period. Most women spend years being treated for anxiety, poor sleep, and stubborn weight. The actual cause goes unaddressed.
Book a ConsultationDr. Sobia Sadiq, MD · Triple Board-Certified: Internal Medicine, Endocrinology & Obesity Medicine
She was 44 when she came to me. She had already been to her gynecologist, her internist, and a therapist. She had been started on an SSRI for anxiety she didn't feel she had, a sleep aid for sleep that had always been fine before, and told repeatedly that her labs were normal. Three different clinicians. Eighteen months. None had measured her hormone levels during the window that mattered.
She wasn't anxious. She wasn't depressed. Her weight changes had a specific driver that no one had looked for. She was perimenopausal. And in a year and a half of appointments, no one had said that word to her.
"I thought I was losing my mind. Nobody had an answer that made any sense."
The Clinical Reality
What Perimenopause Actually Is
Perimenopause is not a single event. It is a transition that typically begins 4 to 10 years before your final menstrual period, often in the early-to-mid 40s, and sometimes earlier. The average age of natural menopause in the US is 51. Many women are in active perimenopause through most of their 40s without a clinician naming it.
The reason this transition is so often missed is that it does not begin with estrogen. It begins with progesterone.
Progesterone drops first.
In the years before estrogen becomes erratic, progesterone quietly declines. Progesterone supports sleep, stabilizes mood, and balances estrogen. When it falls, women often notice worsening PMS, heavier cycles, new anxiety, and disrupted sleep — long before anything shows up on a standard lab panel.
Estrogen then becomes unpredictable. It surges and dips irregularly, driving hot flashes, brain fog, joint pain, and shifts in body composition. To a clinician who is not looking for the pattern, these symptoms look like anxiety, depression, and lifestyle failure.
Three things most women are never told.
- 01Perimenopause can begin before 40.Early perimenopause is not rare and is regularly missed because clinicians expect symptoms to appear in the late 40s. If you are 37 or 38 and your sleep, mood, and cycle have all shifted, this is worth investigating.
- 02Standard labs will often appear normal.A single FSH or estradiol drawn on the wrong day tells you very little. The diagnosis is clinical. Labs inform it. They do not make or exclude it.
- 03Treating symptoms in isolation makes the underlying transition worse.An SSRI for mood and a sleep aid for insomnia do not address the hormonal driver. They manage individual symptoms while the transition continues unchecked.
Beyond Hormones
This Is a Metabolic Story
Perimenopause is not only a reproductive transition. Estrogen is active throughout the body. When levels become unpredictable, the downstream effects reach far beyond your cycle.
Insulin Resistance
Estrogen supports insulin sensitivity in muscle and fat tissue. As estrogen fluctuates and declines, many women become more insulin resistant without any change in diet or activity. This is a direct mechanism behind abdominal fat accumulation and the weight that no longer responds to what used to work.
Lipid Shifts
The SWAN study followed over 3,000 women through the menopausal transition and documented significant LDL increases in the surrounding years. Cardiovascular risk does not hold steady through this transition. It changes.
Study of Women's Health Across the Nation (SWAN), ongoing since 1996Bone Density
Estrogen is a primary regulator of bone remodeling. Bone density loss accelerates significantly in the 3 to 5 years around menopause. This is not a process that becomes relevant at 65. It is happening now, in the perimenopausal years, when it is still modifiable.
Thyroid Overlap
Perimenopausal hormonal shifts frequently worsen thyroid autoimmunity and can alter cortisol patterns. A thyroid problem that was subclinical can become symptomatic during this transition. The symptoms overlap significantly and are regularly misattributed in both directions.
Weight gain in midlife is not a discipline problem. It is a metabolic shift with a specific hormonal mechanism.
Evidence-Based Priorities
What You Can Do Now
Lifestyle intervention during perimenopause is not a substitute for clinical management. It is part of it. These four areas have the strongest evidence for metabolic and hormonal outcomes in midlife women.
Strength Training
Resistance training is the most effective exercise intervention for preserving muscle mass and improving insulin sensitivity during perimenopause. Two to three sessions per week, with progressive loading, is the target. Cardio alone does not address the muscle loss and insulin dynamics of this transition.
Protein Intake
Protein requirements increase with age and hormonal change. Most midlife women eating a typical diet are below what is needed to preserve lean mass. The evidence-informed range is 1.2 to 1.6 grams per kilogram of body weight per day, distributed across meals.
Sleep Quality
Progesterone is naturally sedating. When it drops, sleep architecture changes. Cortisol and insulin dysregulation both worsen with poor sleep, compounding the metabolic effects of the transition. Sleep is not a bonus item. It is a hormonal intervention.
Metabolic Nutrition
Lower glycemic load, adequate fiber, and reduced ultra-processed food directly address the insulin resistance that worsens during the transition. This is about eating in a way that works with your changing insulin sensitivity rather than against it.
At Your Next Appointment
Four Questions Worth Asking
These questions will tell you quickly whether your clinician is seeing your symptoms as a hormonal pattern or managing them one at a time.
A direct question. If your clinician dismisses it without taking a history, that tells you something. If they engage, ask what they would want to measure, when, and on what cycle day.
A progesterone level drawn on the wrong day looks normal even when it is functionally low. Luteal phase is approximately day 18 to 22 of a 28-day cycle. If this has never been timed correctly, you do not have an accurate picture.
Most women are not told that lipid profiles change significantly around menopause. If you have not had a recent lipid panel, ask for one — and ask what you are looking at.
If the answer is no, ask why. A blanket refusal without discussing your personal risk profile, timing, and current evidence on formulation is not a clinical answer. It is a reflex.
The Evidence
What the Research Actually Says About Hormone Therapy
The widespread avoidance of hormone therapy in midlife women traces back largely to the Women's Health Initiative (WHI) study, published in 2002. What most women and many clinicians were not told: the average age of participants in that study was 63. These were not perimenopausal women. They were women more than a decade past menopause.
The risks identified in the WHI for cardiovascular events and breast cancer applied to a specific population, using a specific formulation (conjugated equine estrogen plus medroxyprogesterone acetate), initiated at a specific age. The blanket application of those findings to all women at all ages has not been supported by subsequent evidence.
The Timing Hypothesis
Re-analyses of WHI data and subsequent research indicate that initiating hormone therapy within 10 years of menopause onset, or before age 60, carries a different risk profile than initiating it in older postmenopausal women. The window for cardiovascular protection and symptom relief is precisely the perimenopausal and early postmenopausal years. The same years when most clinicians are still saying "not yet."
Formulation matters.
Not all hormone therapy is the same. Medroxyprogesterone acetate — the synthetic progestin used in the original WHI — has a different risk profile than micronized progesterone. The French E3N cohort and the ESTHER study both found that transdermal estradiol combined with micronized progesterone carried lower VTE risk and a different breast cancer risk profile than oral formulations with synthetic progestins.
This distinction is reflected in prescribing guidelines from NAMS (the North American Menopause Society) and multiple international menopause societies. The formulation conversation belongs in every clinical discussion about HRT.
If You Have Been Told No
A refusal without a discussion of your personal history, your specific risk factors, your timing since menopause, and current evidence on formulation is not an adequate clinical answer. It is an outdated reflex. You are entitled to a reasoned conversation about the evidence as it stands today.
Ready for Answers That Actually Make Sense?
Well Endocrinology is a direct-care endocrinology practice in Hinsdale, IL. No insurance. No referrals. Every visit is with Dr. Sadiq. Initial consultations are 60 minutes.
Book Your Initial Consultationwellendocrinology.com · Hinsdale, IL
